ERBB2 and neoplasm: Group of hormone-positive, lymph node-negative and HER2-positive cases with tumor size exceeding 3 cm presented worse disease-free survival (DFS) rates; thus, authors suggested a potential role of trastuzumab usage in this particular subgroup19.